KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Accumulated Expenses (2017 - 2020)

Aquestive Therapeutics (AQST) has 3 years of Other Accumulated Expenses data on record, last reported at $201000.0 in Q4 2020.

  • For Q4 2020, Other Accumulated Expenses fell 17.28% year-over-year to $201000.0; the TTM value through Dec 2020 reached $201000.0, down 17.28%, while the annual FY2020 figure was $201000.0, 17.28% down from the prior year.
  • Other Accumulated Expenses reached $201000.0 in Q4 2020 per AQST's latest filing, down from $284000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $284000.0 in Q3 2020 and bottomed at $97000.0 in Q1 2020.
  • Average Other Accumulated Expenses over 3 years is $212909.1, with a median of $207000.0 recorded in 2018.
  • The widest YoY moves for Other Accumulated Expenses: up 54.35% in 2020, down 49.48% in 2020.
  • A 3-year view of Other Accumulated Expenses shows it stood at $207000.0 in 2018, then increased by 17.39% to $243000.0 in 2019, then fell by 17.28% to $201000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $201000.0 in Q4 2020, $284000.0 in Q3 2020, and $223000.0 in Q2 2020.